Signatera™
Transforming the management of cancer with personalized testing
Signatera™ is a highly sensitive and personalized molecular residual disease assay (MRD) using circulating tumor DNA (ctDNA), custom designed for each patient to help identify relapse earlier than standard of care tools.
Signatera™ has significant predictive value for long-term patient outcomes
The only significant risk factor in stage II-III colorectal cancer5‑8
In multivariate statistical analysis, MRD status as measured by Signatera™ was the only significant predictor of long-term cancer patient outcomes, after adjusting for all known clinicopathological risk factors including disease stage and lymph node status.1
Will my patient benefit from adjuvant chemotherapy?
Determining which colorectal cancer patients benefit from adjuvant chemotherapy isn’t always clear using current standard of care tools. The GALAXY study set out to better understand if a personalized ctDNA assay can aid risk stratification, better than TNM staging for recurrence.
Check out recent findings published in Nature Medicine
Study Overview: CIRCULATE-Japan (prospective large-scale registry)
- 1,039 patients with Stage II-IV colorectal cancer (CRC), enrolled into the observational GALAXY arm of CIRCULATE-Japan, with median clinical follow up of 16.7 months; a subset of patients received adjuvant treatment (ACT) at physicians’ discretion
- Results were analyzed to determine 18-month disease-free survival (DFS), by molecular residual disease (MRD) status and by treatment status.1
Signatera™ Residual Disease Test (MRD) positivity may be prognostic of survival outcomes post-surgery:
- MRD positivity in patients 4 weeks after surgery were associated with a significantly higher risk of recurrence and inferior disease-free survival (DFS) at 18 months of follow-up (HR 10.0, p value <0.0001), regardless of stage.
When to use Signatera™ MRD test?
Adjuvant setting
- Use after to surgery to evaluate the need for adjuvant chemotherapy
- To personalize and help inform when to escalate or right-size treatment
Surveillance setting
- Detect MRD with greater sensitivity than current standard of care tools
- Use Signatera™ alongside CEA to detect relapse earlier and reduce false positive CEA results
Lajos Pusztai, MD, DPhil
Professor of Medicine (Medical Oncology); Co-Leader, Genetics, Genomics and Epigenetics Research Program, Yale Cancer Center, Yale School of Medicine
Signatera™ can help guide care for your cancer patients
| Risk level | Actionable results: Stage II-III Colorectal | Test Interpretation |
|---|---|---|
| ctDNA High Risk | Consider directed imaging (PET/MRI) to locate the disease while potentially resectable | >97% of patients will relapse |
| ctDNA Reduced Risk | Continue monitoring with reassurance | 12-14% patients may relapse. Patients who remain negative 2 years post treatment have risk reduced to 3% |
Do your patients qualify for the BESPOKE CRC trial?
Our prospective, multicenter study examines the clinical utility of the Signatera™ ctDNA test for monitoring recurrence and guiding treatment decisions in patients with solid tumors. Find out if your patients qualify for the BESPOKE clinical trial.
Medicare Coverage
- Stage II-IV and oligometastatic colorectal cancer (CRC) in the adjuvant and recurrence monitoring settings
- Muscle invasive bladder cancer (MIBC) in the adjuvant and recurrence monitoring settings
- Stage II-IV breast cancer in the neoadjuvant setting, regardless of subtype
- Stage IIb and higher breast cancer in the adjuvant and recurrence monitoring settings
- Stage II-IV ovarian, fallopian tube, or primary peritoneal cancer in the adjuvant and recurrence monitoring settings
- For monitoring of response to immune-checkpoint inhibitor (ICI) therapy for patients with any solid tumor
Commercial Insurance
We will work with patients so that cost is not a barrier for testing.
We offer an affordable self-pay rate for those patients who do not wish to use insurance.
Is Signatera™ right for you?
We’re here to help you find out
1Corcoran RB, Chabner BA. N Engl J Med. 2018;379(18):1754-1765.
2Kramer J, Price ER, Jochelson MS, et al. Eur Radiol. 2017;27(11):4812-4818.
3Borcoman E, Nandikolla A, Long G, Goel S, Le Tourneau C. Am Soc Clin Oncol Educ Book. 2018;38:169-178.
4Perkins GL, Slater ED, Sanders GK, Prichard JG. Am Fam Physician. 2003;68(6):1075-1082.
5Reinert T, Henriksen TV, Christensen E, et al. JAMA Oncol. 2019. doi:10.1001/jamaoncol.2019.0528.
6Sinicrope FA, Foster NR, Thibodeau SN, et al. J Natl Cancer Inst. 2011;103(11):863–875.
7Aoyama, Oba K, Honda M, et al. Cancer Med. 2017;6(7):1573–1580.
8Yothers G, O’Connell MJ, Lopatin M, et al. J Clin Oncol. 2013;31(36):4512-4519.
9Kotani D. et al., Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer, Nature Medicine v29 Issue 1 Jan 2023